In a 52-week open-label trial, tildrakizumab-asmn (Ilumya) reduced a mortality-linked DNA methylation clock by up to 0.5 years while clearing psoriasis symptoms.
Alison Gorman
Advertisement
Alison Gorman recently joined Dermatology Times as a content producer. She is a registered nurse and spent more than a decade as a TV news health reporter. She also served four years as a Nurse Corps Officer in the United States Navy.
You can reach Alison via email at: [email protected]
Articles by Alison Gorman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
How Emerging Androgenetic Alopecia Therapies Target DHT at the Scalp Level
2
Social Media Mythbusters: Beef Tallow
3
The Value of Clinician Collaboration for Skin Cancer Care
4
From Biopsy to Biomarkers: Experts Navigate Skin Cancer Diagnosis and Staging
5